Key Takeaways
- Strong volume, margin squeeze: Standalone revenue grew 21.7% nominal with 10.7% UVG, but gross margin fell 720 bps YoY as VAM costs nearly doubled, pulling EBITDA margin to the lower end of the corridor at 20.4%.
- Input-cost volatility managed, not transmitted: VAM swung from ~$1,000 to over $1,600 within the quarter; management absorbed the whiplash rather than pass it to the market, taking a price increase only on October 1, though they had rebated earlier in the quarter.
- Construction chemicals is the growth engine: Retail and projects momentum is broad-based, the projects business was reorganized by segment, and pioneer categories like renders and wood finishes are advancing from pilot to rollout.
- AI adoption begins, productivity is Phase 2: Top leadership completed hands-on AI workshops and company-wide hackathons are underway; use cases span HR, finance, front-end analytics and manufacturing, but manpower reduction is explicitly deferred to a subsequent discussion.
- What to watch next quarter: Whether the October 1 price increase and potential follow-on round restore gross margins toward the corridor’s upper end, and how much of the projects-business reorganization benefit materializes in Q3.
Volume Growth & Demand
- UVG sustained at double-digit: Underlying volume growth has been double-digit for 6–8 quarters, driven by core brands and construction chemicals; Fevicol alone grew 50–100 bps better than its historical trend.
- Urban demand picked up: Rural growth has historically led, but in Q2 urban growth saw an uptick and was slightly ahead of rural for the first time in a long time; rural growth is holding on.
- Demand is self-created: Management attributes a meaningful portion of volume growth to category creation and market development rather than macro tailwinds, and expects double-digit UVG to persist if India’s real GDP stays in the 6.5–7% range.
- No macro bet built in: The outlook assumes neither an improving nor a worsening macro environment; demand in India is holding up and Q3 has been entered quite well.
- Exports still a drag: Exports out of India into or through West Asia continue to underperform because of regional challenges.
Vats: “If the country's growth is in the 6.5, 7 range in real terms, our UVG growth should remain double digit and we would like to keep inching it up that because a lot of these things we do, we create a lot of demand ourselves.”
Margin Walk & Input-Cost Dynamics
- The VAM shock: VAM consumption rate hit $1,630 in Q2, nearly double YoY and up from $1,370 in Q1, representing the full impact of input-cost inflation hitting the P&L.
- Gross margin fell 720 bps YoY: The entire cost increase has been passed through in absolute terms, but percentage-margin maintenance requires 2x pricing on the cost increase, which cannot be done overnight.
- Q1 cushion, Q2 whiplash: H1 EBITDA stood at 23.5% because Q1 delivered 26.3% on low-cost inventory carryover and proactive replacement-cost pricing; Q2 compressed to 20.4% as VAM first cooled (triggering rebates) then spiked again without a mid-quarter price response.
- Volatility absorbed deliberately: Management chose not to transmit VAM swings to the market intra-quarter, managing pricing on an annual view instead; the October 1 price increase on Fevicol and Dr. Fixit was the first pass-through, with another round possible toward late Q3 or early Q4.
- Crude linkage is real but lagged: The bulk of raw materials are linked to crude, but the linkage is neither instantaneous nor linear because supplier-side demand-supply dynamics and other pressures also shape pricing.
- Operating leverage partially offset the hit: Robust top-line growth absorbed some of the gross-margin compression, limiting the EBITDA decline to 430 bps YoY.
Vats: “We are very clear, as a company and as leaders that we will not transmit this through and through to the market. You cannot say my price in 1 month is like this, second month is like this, third month is like that. We will manage it for the year. We will manage demand as well.”
Batra: “...if you have to be at 50% gross margin, you have to price in 2x of the cost increase to be at the same percentage level of margin. And that's not something that can be done overnight, right?”
Construction Chemicals: Retail & Projects
- Retail momentum is broad: Tile adhesives continue to grow, with Pidilite growing faster than the category and determined to gain share; floor coating is also beginning to see momentum across urban and emerging-India markets.
- Projects business reorganized: In Q2, the team shifted from a small/medium/large project classification to a segment-based approach covering medium/large builders (residential and commercial), hotels/hospitals/education, and EPC contractors; early benefits were visible and more are expected in Q3.
- Pidilite Projects Group formed: The newly constituted PPG is driving strong growth and contributing to the construction-chemicals pipeline.
- Pioneer categories advancing: Grupopuma JV external renders completed 6–7 successful pilots in North India and is now focused on large projects; ICA Pidilite wood finishes has graduated from pioneer to a clear growth category; work is underway on wall finishes.
- NioPro premium tile adhesives: Launched in partnership with Grupopuma, gaining good momentum as a specialized product.
- Render capacity under evaluation: The current Rajasthan facility may be supplemented with additional plants as the rollout builds; interest from architects is growing for commercial, hotel and low-rise residential projects.
Vats: “It's a bit like the duck. There's a lot of paddling happening under the water. You don't see it, it seems calm, but we'll move faster.”
Core Brands & Innovation Pipeline
- Fevicol outperformed its own trend: Growth was 50–100 bps better than in the past, supported by the “Kursi Pe Nazar” campaign in Q1.
- Brand campaigns refreshed across the portfolio: Roff launched a new campaign mid-Q2 and Dr. Fixit launched new copy toward the end of Q2; both will be significantly more visible in Q3.
- New product launches stacked: Araldite Wud X and Araldite Stone X target the premium wood and stone segment; Fevicol Multi Lock and X-Per are piloting and go national in November; M-Seal Advance is piloting with multi-feature claims including easy hand-wash, universal application and low VOCs; Stainoff is seeing good response on quick commerce.
- Domestic subsidiaries broad-based: ICA, construction-chemical subsidiaries (epoxy grouts, marble/stone finish, Wonderproof) all grew north of 20%, with only Nina facing revenue headwinds from inadequate monsoon-season waterproofing workfront.
- International subsidiaries strong: Revenue grew 21.8% and EBITDA grew 53%, led by Dubai, Bangladesh, Kenya and Thailand, all growing over 20%.
Competitive Position & Pricing Philosophy
- No fundamental shift in competitive intensity: Management sees no structural change in the competitive landscape.
- Margin corridor is a strategic choice: The 20–24% EBITDA corridor is deliberate; pushing margins materially higher could compromise the growth opportunity in India and open segments to competitors.
- Profitable volume growth, not volume for its own sake: The mantra is profitable UVG; management is not chasing volume at the expense of margin.
- Medium-term UVG aspiration: The desire is to move UVG from classic double-digit into early teens over time, but the near-term commitment remains double-digit.
- VAM backward integration ruled out: Evaluated multiple times with large international partners; minimum viable scale is large, India has no natural advantage on ethylene or acetic acid, and supply-chain security has not been a challenge even in disruptive times. A competitor’s sub-scale plant was noted but management declined to comment on its rationale.
Vats: “...trying to go really high on margin at times could compromise the growth opportunity in a country like India, could also open up the segments for competitors and make it attractive for wrong reasons.”
Batra: “...we are not chasing volume for volume's sake. For us, the mantra is profitable underlying volume growth.”
AI & Productivity Initiatives
- Phase 1 is capability-building: Top 30 leaders completed a full-day hands-on AI workshop where they themselves coded; the first company-wide AI hackathon is complete and a second is around the corner.
- Use cases identified, not yet harvesting: HR is exploring agentic AI for assessments; finance use cases are under development; front-end analytics cover range selling, customized messaging, influencer management and rapid copy adaptation; manufacturing is applying AI to material-variance reduction and consistent quality; supply-chain work targets reduced response times and network optimization.
- Productivity and manpower reduction are Phase 2: Management is explicit that staff-cost reduction is not a current objective; the focus is on making people more effective and productive, with headcount-related discussions deferred to a subsequent phase, particularly on the front end and possibly in manufacturing.
- Operating leverage already in play: Staff costs are already benefiting from operating leverage; initiatives will help the company grow with limited manpower additions over time.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin corridor | 20–24%, ideally at the slightly higher end | H2 FY27 |
| Price increase | One round taken Oct 1 on Fevicol and Dr. Fixit; another possible | Late Q3 or early Q4 FY27 |
| UVG | Double-digit | Near term (no end date) |
| UVG aspiration | Move from double-digit to early teens | Medium term (no date) |
| Fevicol Multi Lock and X-Per | National launch | November 2026 |
| Roff and Dr. Fixit campaigns | Significantly higher visibility | Q3 FY27 |
| Projects reorganization benefits | Further benefits expected | Q3 FY27 |
| AI manpower reduction | Deferred to Phase 2 discussion | No timeline given |
| VAM backward integration | No plans to set up a plant | Ongoing stance |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Stand-alone revenue | Under ₹4,000 cr, 21.7% nominal growth |
| Underlying volume growth (UVG) | 10.7%, broad-based |
| Consumer & Bazaar UVG | 11.1% |
| B2B UVG | 9.2% |
| Stand-alone EBITDA margin | 20.4%, declined 430 bps YoY; at lower end of 20–24% corridor |
| Gross margin decline | 720 bps YoY, driven by elevated input costs |
| VAM consumption rate | $1,630, nearly double YoY; vs $1,370 in Q1 FY27 |
| H1 FY27 stand-alone revenue growth | 22% |
| H1 FY27 UVG | 11% |
| H1 FY27 EBITDA margin | 23.5%, very much towards the upper end of 20–24% corridor |
| International subsidiaries revenue growth | 21.8% |
| International subsidiaries EBITDA growth | 53% |
| Domestic subsidiaries revenue growth | 22.2% |
| Price increase taken October 1 | 3–5% on Fevicol and Dr. Fixit in areas of heightened inflation; follows 12–15% staggered increase in Q1, with more price increases to come in October |
| Current VAM price | Around $1,200 |